Global Market for Molecular Diagnostics to Exceed $10.7 Billion by 2018, Regenerative Medicine to Top $4.4 Billion

FARMINGTON, Conn., Nov. 28, 2012 /PRNewswire-iReach/ -- With the end of 2012 fast approaching, marketers and business development managers across the globe are turning to Global Information Inc (GII) and our partner publishers to help them determine what lines of business to pursue in 2013. Three significant new market research reports from our premium research partner Global Industry Analysts, Inc. offer vital forecasts for the global molecular diagnostics, regenerative medicine, and flow cytometry markets.

(Photo: http://photos.prnewswire.com/prnh/20121128/CG20288)

The first report examines the global market for molecular diagnostics with an emphasis on how to improve reimbursement for costly and esoteric personalized medicine products. Touted as the next-generation technology to revolutionize the medical care system of the future, a second report provides a comprehensive review of the regenerative medicine market. A third report explores how next generation point-of-care compact systems will drive growth in the global market for flow cytometry.

More details are available below, but parties interested in a more in-depth review of market trends and available research are encouraged to contact Global Information Inc directly at 1.860.674.8796, or online at http://www.giiresearch.com/contact.shtml

Molecular Diagnostics

The global market for molecular diagnostics is forecast to exceed $10.7 billion by 2018. Recent advancements in molecular diagnostics include a shift towards near-patient testing practices, increasing number of innovative biomarkers, and an increased effort for clinically validating tests. In addition, the market is experiencing increasing competition, modifications in the regulatory environment, an improved role of personalized medicine, as well as consolidation within the area of molecular diagnostics.

Major players in the global marketplace include Abbott Laboratories, Life Technologies Corporation, bioMrieux, CytoCore Inc., ELITech Group, GE Healthcare, Genzyme Corp., Hologic Inc., Laboratory Corporation of America Holdings, MiraiBio Inc., Novartis Diagnostics, QIAGEN N.V, Quest Diagnostics Inc., Roche Diagnostics, Siemens Healthcare Diagnostics Inc., and Tecan Group Ltd.

An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/go138654-molecular-diagnostics.html

Regenerative Medicine

Driven by technological advances and favorable demographics, the global market for regenerative medicine is projected to exceed $4.4 billion by 2018. Potentially huge savings on the medical care front and enhanced healing capabilities of regenerative medicine are expected to be the major contributing factors for market growth. Supportive political actions, government funding, corporate investment, clinical outcomes, increased awareness, increased endorsement from doctors, enhanced manufacturing technologies, and novel sources of stem cells are also expected to impart momentum to the growth of regenerative medicine.

View post:
Global Market for Molecular Diagnostics to Exceed $10.7 Billion by 2018, Regenerative Medicine to Top $4.4 Billion